The ALPPS procedure for hepatocellular carcinoma larger than 10 centimeters

• The options of treatment for hepatocellular carcinoma are presented.
• Treatment of huge hepatocellular carcinoma by ALPPS is proposal.
• Better results with ALPPS for hepatocellular carcinoma than other palliative procedures are discussed.
• Selection of patients with huge hepatocellular for ALPPS to achieve good results is important.

IntroductionThe only means of achieving long-term survival in hepatocellular carcinoma is complete tumor resection or liver transplantation. Patients with large hepatocellular carcinomas are currently not considered for liver transplantation. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is indicated in selected patients. We present the case of a patient with a huge hepatocellular carcinoma who underwent an ALPPS procedure. PRESENTATION OF CASE: A 57-year-old man initially presented with a tumor measuring 19 cm × 10 cm in the right lobe of the liver. The liver function was normal and there was no evidence of portal hypertension. The first part of the procedure was performed without mobilizing the liver. The middle hepatic vein was divided during parenchymal transection. The second procedure was performed after 15 days. During that procedure the right hepatic artery, right bile duct, and the right hepatic vein were ligated and divided. Liver segments 4–8 with the tumor were removed. The patient developed moderate ascites but recovered after ten days. After 90 days, the patient is doing well with no signs of recurrence.DiscussionHepatocellular carcinoma is a complicated disease and ALPPS is not considered an optimal treatment option. However, patients with large tumors are not considered for liver transplantation or chemotherapy. Patients with Child-Pugh A liver disease without portal hypertension can benefit from surgical treatment for hepatocellular carcinoma; in some situations, surgery may be considerably better than other forms of treatment.ConclusionALPPS should be considered in selected patients with large hepatocellular carcinomas.